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We have performed a broad-ranging analysis of the adjuvant effect of a Kampo medicine, juzentaihoto (JTT), on influenza
vaccination in a multicenter randomized controlled trial. In this study, the enhancing effect of JTT on antibody titer after influenza
vaccination was studied for 28 weeks in elderly people who were in the high-risk group for influenza infection. In total, 91 subjects
over 65 years old were recruited from four long-term-care facilities located in Chiba, Gunma, and Toyama prefectures in Japan.
Participants were randomly assigned to the JTT and the control groups. Blood samples were taken at 4 weeks before vaccination,
at the time of vaccination, and then at 4, 8, 12, and 24 weeks after vaccination. The hemagglutination inhibition (HI) titers against
A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 were then manually measured. A significant
increase in HI titer against H3N2 was observed at week 8 after vaccination in the JTT group compared with the control group
(𝑃 = 0.0229), and the HI titer of the JTT group significantly increased from 4 to 24 weeks (𝑃 = 0.0468), compared with the control
group. In conclusion, our results indicated that JTT increased and prolonged antibody production against A/Victoria/210/2009
(H3N2), in particular, after influenza vaccination.
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1. Introduction
Influenza vaccination is an important procedure for protect-
ing against influenza infection. Vaccine adjuvants that induce
the specific immune responses against the vaccine antigens
are valuable for enhancing the efficacy of influenza vaccines
by increasing and maintaining antibody production.
Some Kampo formulas, such as juzentaihoto (JTT), have
been reported to show nonspecific preventive effects against
influenza infection [1]. Some basic studies have shown that
JTT enhanced immune cell function such as natural killer cell
activity [2], cytokine production [3], and immunoadjuvant
activity against human papillomavirus [4].
In the present study, we investigated the adjuvant effect of
long-term administration of JTT on influenza vaccination in
a randomized controlled trial among elderly people whomay
be in the high-risk group for influenza infection.
2. Materials and Methods
2.1. Participants. Subjects over 65 years old were recruited
from four long-term-care facilities (Akiba Clinic of Tra-
ditional Medicine in Chiba Prefecture, Ninosawa Hospital
in Gunma Prefecture, Tonami Miwa Hospital and Sanbari
Takaoka Hospital in Toyama Prefecture) in Japan. Patients
with severe infection, neoplastic disease, or poor general
conditionwere excluded. At baseline, each patient underwent
a uniform evaluation that included medical history, principal
disease, main complications, and the degree of nursing care.
A total of 91 patients (22 men and 69 women: mean age ±
SD, 85.6 ± 8.1 years) were enrolled, but one patient withdrew
before the allocation, leaving a total of 90 participants. These
patients were randomly allocated into either the JTT group
(𝑛 = 44) or the control group (𝑛 = 46) (Figure 1). No sig-
nificant differences were noted between the two groups in
terms of age (85.6 ± 8.2 and 85.5 ± 8.3 year, resp.) or duration
of hospitalization (35.6 ± 29.8 and 37.9 ± 35.5months, resp.).
Original diseases in these patients included cerebral vascular
disease in 54 patients, dementia in 37, and bone and joint
diseases in 14. Regarding the ranks of care, 8 patients were
in Rank 1, 7 patients were in Rank 2, 10 patients were in Rank
3, 17 patients were in Rank 4, and 48 patients were in Rank
5. Almost all of them were bedridden patients (Table 1). HI
titer was measured twice before vaccination (−4 week and 0
week). As a result, both HI in JTT and control group were
guaranteed to be the same level statistically. The study design
was approved by the Human Subjects Committee, University
of Toyama. All patients provided written informed consent
in accordance with ethical guidelines set forth in the 1975
Declaration of Helsinki.
2.2. Intervention Protocol. A 28-week randomized controlled
trial was begun between October 2011 and April 2012.
Participants were assigned to the JTT and control groups
using the allocation software managed by bystander. The
extract of JTT, which is approved for medical use in Japan,
was purchased from Kracie Holdings, Ltd. (Tokyo, Japan).
It consists of ten herbs: 3 g each of Astragali radix (roots of
Astragalus membranaceus Bunge), Cinnamomi cortex (bark
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Figure 1: Flow chart of subject recruitment and trial profiles.
Table 1: Clinical and demographic characteristics of study partici-
pants.
Group JTT group Control group
Sex (male/female) 10/34 11/35
Age (year), mean ± SD 85.6 ± 8.2 85.5 ± 8.3
Duration of hospitalization
(month), mean ± SD 35.6 ± 29.8 37.9 ± 35.5
Chief disease (number)
Cerebral vascular disorder 26 28
Dementia 19 18
Bone and joint disease 6 8
Rank of care (number)
Rank 1 3 5
Rank 2 3 4
Rank 3 6 4
Rank 4 9 8
Rank 5 23 25
Note. All group comparisons 𝑃 > 0.05. SD: standard deviation; JTT:
Juzentaihoto.
Rank 1: patients who need partial help with personal care. Rank 2: patients
who need partial help with eating or going to the toilet and so forth. Rank
3: patients who need full help with certain activities of daily living. Rank 4:
patients who have difficulty performing all daily activities without help. Rank
5: patients who find it impossible to perform all daily activities without help.
of Cinnamomum cassia Blume), Rehmanniae radix (root of
Rehmannia glutinosaLibosch var. purpureaMakino), Paeonia
radix (rhizome of Paeonia lactiflora Pall), Cnidii rhizoma
Evidence-Based Complementary and Alternative Medicine 3
(rhizome ofCnidium officinaleMakino), Atractylodis lanceae
rhizoma (rhizome of Atractylodes lancea DC), Angelicae
radix (root of Angelica acutiloba Kitagawa), Ginseng radix
(root of Panax ginseng C. A. Meyer), Hoelen (fungus of
Poria cocos Wolf), and 1.5 g of Glycyrrhizae radix (root of
Glycyrrhiza uralensis Fisch et DC). The aqueous extract was
lyophilized to obtain a powder. Fine grains (7.5 g) consist of
lactose (1.3 g) and the aqueous extract (6.2 g).
The quality of the JTT extract was confirmed by its 3D
HPLC pattern [5]. Subjects in the JTT group were admin-
istered JTT at 7.5 g/day, 3.75 g two times daily, orally or
through a tube after meals, from 4 weeks before to 24
weeks after vaccination. Those in the control group were
not administered Kampo medication but continued to take
their regular medication. The premixed vaccine contained
15 𝜇g of each of following hemagglutinin (HA) antigens:
A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2),
and B/Brisbane/60/2008. A subcutaneous injection of 0.5mL
of vaccinewas given once at week 0.This studywas conducted
as an open-label study since it was impossible to prepare a
suitable placebo due to the unique flavor and odor of JTT.
2.3. Outcome Determination. Blood samples were taken at
weeks −4, 0, 4, 8, 12, and 24. Serum samples were kept frozen
at −80∘C until analysis. Antibody titers to hemagglutinin
were measured by a standard microtiter hemagglutination
inhibition method [6]. Blood biochemistry was measured by
standardmethods as follows: albumin (Alb) wasmeasured by
a BCG method. Aspartate aminotransferase (AST), alanine
aminotransferase (ALT), lactate dehydrogenase (LDH), and
blood urea nitrogen (BUN) were measured by a UVmethod.
Alkaline phosphatase (ALP) was measured by a colorimet-
ric method. Creatinine (Cr) was measured by an enzyme
method.Natrium (Na), potassium (K), and chloride (Cl)were
measured by an electrode method.
2.4. Statistical Analysis. Data are expressed as means ± SD.
Blood biochemistry data of the two groups were compared at
weeks −4, 0, 4, 8, 12, and 24 with the Student’s 𝑡-test.
HI titers of the two groups were compared at weeks
4, 8, 12, and 24 with the Cochran-Armitage trend test.
The two groups were compared from 4 to 24 weeks by
the nonparametric repeated analysis of variance (ANOVA)
where HI titers had been transformed into ordinal data. A
𝑃 value < 0.05 was considered statistically significant. The
nonparametric version means that the titer data were trans-
formed into ordinal data such as “less than 10 times” into
“0”; “10 times” into “1”; “20 times” into “2”; “40 times” into
“3”; “80 times” into “4”; “160 times” into “5”; “320 times”
into “6”; “640 times” into “7”; and “1280 times” into “8” on
this occasion. The reason of transforming the data was that
original titer data were strongly right skewed. A 𝑃 value <
0.05 was considered to indicate statistical significance.
3. Results
3.1. Characteristics of Participants. Twelve JTT subjects
dropped out of the study due to primary disease progression
(𝑛 = 4), revocation of agreement and drug refusal (𝑛 = 3),
impossibility of oral intake before starting the study (𝑛 = 2),
ileus (𝑛 = 1), cerebral infarction (𝑛 = 1), or stomach distress
(𝑛 = 1). Two control subjects also dropped out due to primary
disease progression (𝑛 = 1) and revocation of agreement (𝑛 =
1). No subject contracted influenza during the study period.
Data were analyzed with the remaining 76 subjects (32 and 44
in the JTT and control groups, resp.). Throughout the study
period, obvious adverse events with JTT were noted in one
subject, who developed epigastric distress and stopped taking
JTT. Thereafter, his symptoms disappeared. JTT contains
Glycyrrhiza, which may induce hypokalemia, but no subjects
showed decreased serum potassium in this study. No other
major blood biochemistry changes occurred before and
after the study in the JTT and control groups statistically
(Table 2).
3.2. Comparison of the HI Titers of the JTT and Control
Groups at Weeks −4, 0, 4, 8, 12, and 24. The number of group
members who had high HI titers for A/Victoria/210/2009
(H3N2) tended to increase in the JTT group compared with
the control group at weeks 4, 12, and 24 (𝑃 = 0.0739,
𝑃 = 0.0849, and 𝑃 = 0.0895, resp.). The number of
group members with a high HI titer significantly increased
in the JTT group compared to the control group at week 8
(𝑃 = 0.0229). In contrast, no significant difference was noted
between the two groups for the titers for A/California/7/2009
(H1N1) or B/Brisbane/60/2008 in any week (Table 3). One
sample at 24 weeks in the JTT group could not be measured
for lack of volume. Thus, the number of samples at 24 weeks
in the JTT group was 31 samples.
3.3. Comparison of the Changes of HI Titer for H3N2 from
−4 to 24 Weeks in the JTT and Control Groups. The changes
in HI titer for H3N2 significantly increased in the JTT
group compared with the control group from 4 to 24 weeks
(𝑃 = 0.0468). However, no significant difference was noted
between the two groups for H1N1 or B (Figure 2).
4. Discussion
This study was designed to examine the adjuvant effect of
JTT on the administration of influenza vaccine in a long-
term study in elderly people using a multicenter randomized
controlled trial with the goal of increasing the effects of
antibody production. Overall, the number of patients with a
highHI titer tended to increase in the JTT groupmore than in
the control group at 4 weeks and was significantly increased
at 8 weeks for A/Victoria/210/2009 (H3N2). This tendency
toward an increase continued until 24 weeks.
This result makes it clear that there is a significant
difference between the JTT group and the control group on
the time course of their HI titers of H3N2 by ANOVA.These
results showed that JTT had an adjuvant effect especially for
the A/Victoria/210/2009 (H3N2) vaccine.
Because the HI titer was measured twice before vacci-
nation (−4 weeks and 0 weeks), HI in both the JTT group
and the control group was guaranteed to be at the same
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Table 2: Changes in blood biochemistry data of JTT and control groups.
Group −4 weeks 0 week 4 weeks 8 weeks 12 weeks 24 weeks
Alb (g/dL) JTT (n = 42–32) 3.6 ± 0.37 3.5 ± 0.28 3.6 ± 0.31 3.7 ± 0.32 3.6 ± 0.31 3.4 ± 0.49
Cont (n = 45–44) 3.6 ± 0.43 3.6 ± 0.42 3.7 ± 0.45 3.6 ± 0.40 3.7 ± 0.47 3.6 ± 0.42
AST (IU/L) JTT (n = 42–32) 23.4 ± 10.2 22.9 ± 10.8 24.0 ± 11.9 24.8 ± 10.8 26.1 ± 17.7 24.6 ± 10.0
Cont (n = 45–44) 22.0 ± 7.2 25.0 ± 12.0 23.9 ± 9.5 23.0 ± 7.4 23.2 ± 7.0 23.4 ± 7.4
ALT (IU/L) JTT (n = 42–32) 19.9 ± 13.4 18.1 ± 13.0 18.3 ± 12.7 19.9 ± 15.0 20.5 ± 17.2 20.5 ± 15.3
Cont (n = 45–44) 18.1 ± 9.5 20.7 ± 14.6 18.8 ± 12.3 18.0 ± 10.0 17.3 ± 9.0 17.9 ± 9.0
LDH (IU/L) JTT (n = 42–32) 168.0 ± 30.1 175.8 ± 33.1 179.5 ± 47.2 180.3 ± 43.1 180.4 ± 43.3 194.9 ± 55.0
Cont (n = 45–44) 177.8 ± 39.0 186.7 ± 50.3 179.2 ± 43.9 176.7 ± 38.3 183.7 ± 41.4 185.2 ± 41.2
ALP (IU/L) JTT (n = 42–32) 379.4 ± 465.0 363.8 ± 432.7 379.7 ± 454.4 379.1 ± 402.7 398.6 ± 461.7 404.8 ± 385.7
Cont (n = 45–44) 278.3 ± 62.8 280.0 ± 66.7 293.6 ± 82.2 289.9 ± 71.0 297.2 ± 75.6 319.3 ± 94.4
BUN (mg/dL) JTT (n = 42–32) 21.1 ± 9.7 19.0 ± 8.7 19.9 ± 8.9 20.7 ± 9.5 20.0 ± 8.6 21.5 ± 10.6
Cont (n = 45–44) 17.6 ± 5.6 16.9 ± 6.3 18.1 ± 5.9 17.0 ± 6.1 17.2 ± 5.4 18.1 ± 5.3
Cr (mg/dL) JTT (n = 42–32) 0.82 ± 0.45 0.70 ± 0.36 0.68 ± 0.36 0.68 ± 0.34 0.69 ± 0.36 0.71 ± 0.42
Cont (n = 45–44) 0.70 ± 0.22 0.64 ± 0.20 0.64 ± 0.20 0.64 ± 0.21 0.64 ± 0.20 0.64 ± 0.19
Na (mEq/L) JTT (n = 42–32) 138.1 ± 5.8 138.1 ± 5.0 139.7 ± 5.1 138.8 ± 4.8 139.3 ± 4.9 139.0 ± 5.1
Cont (n = 45–44) 138.6 ± 4.2 137.5 ± 4.8 139.0 ± 4.6 137.6 ± 3.9 138.6 ± 3.6 138.6 ± 3.6
K (mEq/L) JTT (n = 42–32) 4.17 ± 0.50 4.10 ± 0.55 4.09 ± 0.62 4.46 ± 0.59 4.30 ± 0.51 4.23 ± 0.67
Cont (n = 45–44) 3.88 ± 0.43 4.05 ± 0.45 4.18 ± 0.44 4.65 ± 0.74 4.42 ± 0.62 4.41 ± 0.69
Cl (mEq/L) JTT (n = 42–32) 99.8 ± 5.7 100.0 ± 4.7 100.6 ± 4.1 100.1 ± 4.7 100.7 ± 4.6 99.3 ± 5.2
Cont (n = 45–44) 100.0 ± 4.2 99.4 ± 5.0 100.3 ± 4.2 100.0 ± 4.2 100.3 ± 3.7 99.7 ± 3.5
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Figure 2: Changes in HI titer after vaccination. (a) A/California/7/2009 (H1N1), (b) A/Victoria/210/2009 (H3N2), and (c) B/Brisbane/60/
2008.TheHI titer significantly increased for A/Victoria/210/2009 (H3N2) in the JTT group compared to the control group from 4 to 24 weeks
after JTT administration and vaccination (mean ± SD, 𝑃 = 0.0468).
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Table 3: Comparison in number of the JTT group and the control group on every HI titer at weeks −4, 0, 4, 8, 12, and 24.
Number of every HI titer (times)
<10 10 20 40 80 160 320 640 1280 𝑃 value
A/California/7/2009 (H1N1)
−4 weeks
JTT (𝑛 = 42) 13 12 10 2 4 1 0 0 0
Cont (𝑛 = 45) 14 11 5 11 4 0 0 0 0
0 week
JTT (𝑛 = 37) 12 10 9 2 3 1 0 0 0
Cont (𝑛 = 45) 13 12 5 11 4 0 0 0 0
4 weeks
JTT (𝑛 = 36) 3 10 7 7 7 0 2 0 0 0.8235
Cont (𝑛 = 44) 2 10 12 10 7 3 0 0 0
8 weeks
JTT (𝑛 = 34) 2 9 8 7 4 2 2 0 0 0.3529
Cont (𝑛 = 44) 6 11 7 10 10 0 0 0 0
12 weeks
JTT (𝑛 = 33) 8 10 6 4 3 2 0 0 0 0.4028
Cont (𝑛 = 45) 11 16 6 11 1 0 0 0 0
24 weeks
JTT (𝑛 = 31) 3 8 10 4 4 2 0 0 0 0.2848
Cont (𝑛 = 44) 9 12 5 15 3 0 0 0 0
A/Victoria/210/2009 (H3N2)
−4 weeks
JTT (𝑛 = 42) 8 11 10 6 4 3 0 0 0
Cont (𝑛 = 45) 4 15 15 6 4 1 0 0 0
0 week
JTT (𝑛 = 37) 6 11 9 4 4 3 0 0 0
Cont (𝑛 = 45) 4 14 16 6 4 1 0 0 0
4 weeks
JTT (𝑛 = 36) 1 8 5 5 8 6 2 0 1 0.0739
Cont (𝑛 = 44) 1 10 9 18 3 1 1 1 0
8 weeks
JTT (𝑛 = 34) 0 5 6 7 6 5 4 0 1 0.0229
Cont (𝑛 = 44) 0 7 14 15 5 1 1 0 1
12 weeks
JTT (𝑛 = 33) 1 8 5 7 7 3 1 0 1 0.0849
Cont (𝑛 = 45) 2 15 8 14 4 0 1 0 1
24 weeks
JTT (𝑛 = 31) 0 8 5 8 6 2 1 0 1 0.0895
Cont (𝑛 = 44) 1 13 12 12 4 1 0 0 1
B/Brisbane/60/2008
−4 weeks
JTT (𝑛 = 42) 12 17 5 6 2 0 0 0 0
Cont (𝑛 = 45) 10 23 4 7 0 1 0 0 0
0 week
JTT (𝑛 = 37) 11 15 5 4 2 0 0 0 0
Cont (𝑛 = 45) 10 20 8 6 0 1 0 0 0
4 weeks
JTT (𝑛 = 36) 4 19 10 3 0 0 0 0 0 0.2576
Cont (𝑛 = 44) 9 21 13 1 0 0 0 0 0
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Table 3: Continued.
Number of every HI titer (times)
<10 10 20 40 80 160 320 640 1280 𝑃 value
8 weeks
JTT (𝑛 = 34) 7 15 8 3 1 0 0 0 0 0.4411
Cont (𝑛 = 44) 13 19 8 3 0 1 0 0 0
12 weeks
JTT (𝑛 = 33) 3 17 8 4 1 0 0 0 0 0.2610
Cont (𝑛 = 45) 3 32 6 3 1 0 0 0 0
24 weeks
JTT (𝑛 = 31) 1 16 13 1 0 0 0 0 0 0.6710
Cont (𝑛 = 44) 1 28 13 1 1 0 0 0 0
level statistically. Therefore, the assignment of participants is
thought to be no issue.
It is generally known that the H1N1 influenza A virus
caused the catastrophic and historic pandemic in 1918-1919,
and that the 1968-1969 pandemic was caused by the H3N2
influenza A virus. However, the genetic background of the
present seasonal H1N1 and H3N2 viruses has not changed
from the pandemic H1N1 of 1918-1919 and the pandemic
H3N2 of 1968-1969, respectively [7]. Taking the average
age of the 91 participants (85.6 years) into consideration,
it is very likely that the participants were infected with
pandemic H3N2 in 1968-1969, not but with pandemic H1N1
in 1918-1919. Therefore, the present seasonal H3N2 influenza
vaccine might strongly affect the immunoresponse in elderly
participants because this vaccine was prepared from the
seasonal H3N2 influenza virus, which is the same as the
pandemic H3N2 from 1968-1969.
In addition, the possibility cannot be denied that the
present seasonal H3N2 influenza vaccine has high immuno-
genicity. In fact, two previous randomized trials have
reported on antibody production after influenza vaccination
with Kampo medicines. The first one was a trial using
maobushisaishinto (MBST), which is often used to treat
bronchitis patients. The mean HI titer against H3N2 sig-
nificantly increased in the group taking MBST for three
weeks before or after influenza vaccination compared to the
control group, at 4 weeks after influenza vaccination [8].
However, no prolonged effect of MBST was reported because
no observations were made over time.
On the other hand, the second was a trial on the effect
of hochuekkito (HET), which, like JTT, is frequently used to
improve chronic fatigue. In this study, healthy adults were
administered HET orally for two weeks before influenza
vaccination, and then the variability of the mean HI titer
was measured from week 0 to week 12 after influenza vacci-
nation. No discernible difference was noted in the antibody
production between the HET group and the control group
[9]. One explanation for this negative result may be that
this study was designed for healthy adults whose ability for
antibody production did not decrease, unlike the case for
elderly people, and the subjects maintained a normal titer
level. Basic research on HET has indicated an ability to
increase IgA antibody production against a model vaccine
antigen [10]. In a clinical study, administration of HET
potentiated the natural killer cell activity in elderly people
[11]. These results suggest that the adjuvant effects of Kampo
medicines on influenza vaccination should be appropriately
determined based on the types of Kampo medicine, the
length of treatment, and the types of patients, and so forth.
Clinically, JTT has been used to improve conditions
such as chronic fatigue, postoperative decline, anorexia, and
anemia. It has also shown effectiveness in treating various
symptoms and restoring strength in elderly people and has
proven suitable for long-term administration [12]. Some clin-
ical reports on JTT have shown hematopoiesis and anemia
recovery [13–15]. JTT has been used as an adjunctive therapy
for advanced breast cancer patients [16]. A recent report
indicated that JTT aided in preventing the recurrence of otitis
[17].
JTT is prescribed for various diseases, and one of its
mechanisms of action is to augment the immune system
through anticancer effects due to immunopotentiation [3].
Some studies have reported that JTT stimulates antibody
production in tumor-bearingmice [18, 19] and that the pectic
polysaccharide contained in JTT is partly associated with
this increase in antibody production [20]. JTT has been
also shown to act as a vaccine adjuvant to stimulate an
immune response against human papillomavirus in mice [4].
However, clinical randomized controlled trials of JTT and
antibody production have not yet been carried out.
The present study indicates that JTT is a useful Kampo
formulation to augment the efficacy of influenza vaccination
of elderly people/patients whose ability to produce antibodies
may be impaired. Although no severe side effects have been
reported for JTT [14, 17, 21]. In the early stage, many patients
dropped out of JTT group in comparison with control group.
One of the reasons may be that some elderly people rejected
oral administration of JTT because they disliked its taste.
Furthermore, four patients whose preexisting diseases
worsened became decreasingly able to take JTT orally and
eventually stopped. Meanwhile, because they did not take a
placebo in this study, there were few patients in the control
group who dropped out. In the present study, a direct adverse
effect of JTT was indicated by the one case in which there was
a complaint of a heavy feeling in the stomach.
In the present study, a direct adverse effect of JTT was
indicated by the one case who complained of a heavy feeling
in the stomach.
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Finally, further investigation of the active components in
JTT is necessary to augment the influenza vaccination as well
as to establish its mechanisms of action. The optimal period
for intake and suitable conditions for subjects also require
clinical study.
5. Conclusion
The adjuvant effects of JTT on influenza vaccination were
studied in elderly patients in long-term-care facilities.
JTT increased and prolonged antibody production against
A/Victoria/210/2009 (H3N2) after influenza vaccination at 8
weeks.
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